Amgen, Simcere partner for biosimilars in China

Amgen Inc. (NASDAQ:AMGN) and Simcere Pharmaceutical Group (Nanjing, China) partnered to exclusively co-develop and commercialize biosimilars in China. The agreement includes four biosimilars from Amgen in inflammation and oncology, including ABP 501 and Mvasi bevacizumab-awwb (ABP 215).

Amgen said the deal will allow it to leverage Simcere's local drug development experience and "strong commercial presence in China in the areas of inflammation and oncology." Simcere will be in charge of commercializing the products in China, while Amgen will be responsible for submitting regulatory applications and manufacturing. Amgen will also have "limited" co-promotion rights. Financial terms were not disclosed...